# Urologix, Inc. (ULGX)

> Source: Nexqual · https://nexqual.com/ULGX · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Urologix, Inc. (ULGX), nexqual.com/ULGX" · informational, not investment advice.

**Price:** USD 0 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0 · day 0–0 · 52w 0–0.01 · market cap $2K · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +13.4%; 5Y -50.0% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +0.0% | -50.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +0.0% | -13.0% |
| Volatility (annualized) | 98.6% | 185.2% |
| Max drawdown | -50.0% (Feb 2026→Mar 2026) | -95.0% (Oct 2021→Apr 2023) |

## Peers (Medical Devices)
ATEC (Alphatec Holdings, Inc.) USD 11.11 -2.20% · BFLY (Butterfly Network, Inc.) USD 6.76 -0.73% · ESTA (Establishment Labs Holdings Inc) USD 63.8 +0.44% · INSP (Inspire Medical Systems, Inc.) USD 71.11 -2.13% · ALMR (Alamar Biosciences, Inc.) USD 30.69 +3.26% · AXGN (AxoGen, Inc.) USD 38.06 +3.76%

## More
Full page: https://nexqual.com/ULGX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2013-06-30) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |